Status:
COMPLETED
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.
Eligibility Criteria
Inclusion
- Documented clinical history of chronic hepatitis C and compensated liver disease
- No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant or breastfeeding
- Patient is co-infected with HBV or HIV
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00227435
Start Date
February 1 2003
End Date
July 1 2004
Last Update
April 27 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pasadena, California, United States
2
Boston, Massachusetts, United States
3
Worcester, Massachusetts, United States
4
Fairfax, Virginia, United States